Abstract
Mosquito-borne tropical dengue disease is a major global epidemic affecting hundreds of millions of people. As a precaution, it would be ideal to develop a highly efficient tetravalent vaccine that protects against all serotypes of dengue viruses. In this study, envelope protein domain III (EDIII) of dengue virus was employed as a target antigen. A single-chain tetravalent type of EDIII (tEDIII) was generated by utilizing a linker peptide and transformed into rice (Oryza sativa). Integration and mRNA transcripts of the tEDIII gene were confirmed by genomic DNA polymerase chain reaction (PCR) and Northern blot analyses, respectively. The expression of wild-type tEDIII (wtEDIII) protein was confirmed by Western blot analysis and was determined to improve the synthesis of the tEDIII (stEDIII) construct based on codon optimization and ER targeting. The yield of stEDIII protein was sevenfold higher than secreted wtEDIII protein, reaching a maximum of 357 µg per gram dry weight. These results suggest that a simple tetravalent EDIII dengue antigen can be produced in rice, raising the possibility that edible plant cells can be vaccinated by mucosal application for protection against dengue infection.
Similar content being viewed by others
References
Adang MJ, Brody MS, Cardineau G, Eagan N, Roush RT, Shewmaker CK, Jones A, Oakes JV, McBride KE (1993) The reconstruction and expression of a Bacillus thuringiensis cryIIIA gene in protoplasts and potato plants. Plant Mol Biol 21(6):1131–1145
Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, Skinner C, Diehl L, Lyons R, Porter K, Punnonen J (2006) Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24(3):335–344
Arakawa T, Chong DK, Merritt JL, Langridge WH (1997) Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res 6(6):403–413
Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ (2010) A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 28(51):8085–8094
Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Despres P, Tangy F (2010) “Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28(41):6730–6739
Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D (2011) Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I. Trial in the Philippines. Vaccine 29(22):3863–3872
Chan MT, Chang HH, Ho SL, Tong WF, Yu SM (1993) “Agrobacterium-mediated production of transgenic rice plants expressing a chimeric alpha-amylase promoter/beta-glucuronidase gene. Plant Mol Biol 22(3):491–506
Chen Y, Maguire T, Marks RM (1996) Demonstration of binding of dengue virus envelope protein to target cells. J Virol 70(12):8765–8772
Chen TL, Lin YL, Lee YL, Yang NS, Chan MT (2004) Expression of bioactive human interferon-gamma in transgenic rice cell suspension cultures. Transgenic Res 13(5):499–510
Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E (2007) Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol 26(6):361–367
Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Chong P, Leng CH, Chen HW (2011) A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 6(8):e23319
Christou P (1997) Rice transformation: bombardment. Plant Mol Biol 35(1–2):197–203
Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75(16):7769–7773
Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69(6 Suppl):48–60
Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, Khanna N (2008) An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 79(3):353–363
Fernandez-San Millan A, Mingo-Castel A, Miller M, Daniell H (2003) A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J 1(2):71–79
Fischer R, Schumann D, Zimmermann S, Drossard J, Sack M, Schillberg S (1999) Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. Eur J Biochem 262(3):810–816
Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW (2010a) Dengue: a continuing global threat. Nat Rev Microbiol 8(12 Suppl):S7–S16
Hernandez M, Rosas G, Cervantes J, Fragoso G, Rosales-Mendoza S, Sciutto E (2014) Transgenic plants: a 5-year update on oral antipathogen vaccine development. Expert Rev Vaccines 13(12):1523–1536
Hong SY, Kwon TH, Jang YS, Kim SH, Yang MS (2006) Production of bioactive human granulocyte-colony stimulating factor in transgenic rice cell suspension cultures. Protein Expr Purif 47(1):68–73
Horn ME, Woodard SL, Howard JA (2004) Plant molecular farming: systems and products. Plant Cell Rep 22(10):711–720
Huang J, Sutliff TD, Wu L, Nandi S, Benge K, Terashima M, Ralston AH, Drohan W, Huang N, Rodriguez RL (2001) Expression and purification of functional human alpha-1-Antitrypsin from cultured plant cells. Biotechnol Prog 17(1):126–133
Huang J, Wu L, Yalda D, Adkins Y, Kelleher SL, Crane M, Lonnerdal B, Rodriguez RL, Huang N (2002) Expression of functional recombinant human lysozyme in transgenic rice cell culture. Transgenic Res 11(3):229–239
Huang LF, Liu YK, Lu CA, Hsieh SL, Yu SM (2005) Production of human serum albumin by sugar starvation induced promoter and rice cell culture. Transgenic Res 14(5):569–581
Huang LF, Tan CC, Yeh JF, Liu HY, Liu YK, Ho SL, Lu CA (2015) Efficient secretion of recombinant proteins from rice suspension-cultured cells modulated by the choice of signal peptide. PLoS One 10(10):e0140812
Hurrelbrink RJ, McMinn PC (2003) Molecular determinants of virulence: the structural and functional basis for flavivirus attenuation. Adv Virus Res 60:1–42
Innis BL, Eckels KH (2003) Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69(6 Suppl):1–4
Kang TJ, Han SC, Jang MO, Kang KH, Jang YS, Yang MS (2004) Enhanced expression of B-subunit of Escherichia coli heat-labile enterotoxin in tobacco by optimization of coding sequence. Appl Biochem Biotechnol 117(3):175–187
Khanam S, Khanna N, Swaminathan S (2006) Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24(42–43):6513–6525
Khanam S, Pilankatta R, Khanna N, Swaminathan S (2009) An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27(43):6011–6021
Kim MY, Yang MS, Kim TG (2009) Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants. Biotechnol Bioprocess Eng 14(6):725–730
Kim MY, Yang MS, Kim TG (2012) Expression of a consensus dengue virus envelope protein domain III in transgenic callus of rice. Plant Cell Tissue Organ Culture 109(3):509–515
Kim TG, Kim MY, Huy NX, Kim SH, Yang MS (2013a) M cell-targeting ligand and consensus dengue virus envelope protein domain III fusion protein production in transgenic rice calli. Mol Biotechnol 54(3):880–887
Kim MY, Chung ND, Yang MS, Kim TG (2013b) “Expression of a cholera toxin B subunit and consensus dengue virus envelope protein domain III fusion gene in transgenic rice callus. Plant Cell Tissue Organ Culture 112(3):311–320
Kim TG, Kim MY, Tien NQ, Huy NX, Yang MS (2014) Dengue virus E glycoprotein production in transgenic rice callus. Mol Biotechnol 56(12):1069–1078
Kim MY, Kim BY, Oh SM, Reljic R, Jang YS, Yang MS (2016) Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes. Plant Mol Biol 92(3):347–356
Kim MY, Van Dolleweerd C, Copland A, Paul MJ, Hofmann S, Webster GR, Julik E, Ceballos-Olvera I, Reyes-Del J, Valle MS, Yang YS, Jang R, Reljic, Ma JK (2017) Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate. Plant Biotechnol J 15:1590–1601
Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF (2006) Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24(9):1238–1241
Konishi E, Kosugi S, Imoto J (2006) “Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24(12):2200–2207
Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus AD (2007) Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine 25(29):5409–5416
Laguia-Becher M, Martin V, Kraemer M, Corigliano M, Yacono ML, Goldman A, Clemente M (2010) Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. BMC Biotechnol 10:52
Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Lien SP, Yueh A, Hsiao KN, Lai LW, Liu FC, Chong P, Chen HW (2009) A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11(2):288–295
Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Stroher U, Uyeki TM, Ribner BS, U. Emory Serious Communicable Diseases (2014) Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371(25):2402–2409
Maves RC, Ore RM, Porter KR, Kochel TJ (2011) “Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 29(15):2691–2696
Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, Van Regenmortel MH et al (1992) Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187(2):480–491
Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C (2005) Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23(26):3469–3476
Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3(1):13–22
Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587–619
Nguyen NL, Kim JM, Park JA, Park SM, Jang YS, Yang MS, Kim DH (2013) Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae. Protein Expr Purif 88(2):235–242
Pang T, Cardosa MJ, Guzman MG (2007) Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85(1):43–45
Perlak FJ, Fuchs RL, Dean DA, McPherson SL, Fischhoff DA (1991) Modification of the coding sequence enhances plant expression of insect control protein genes. Proc Natl Acad Sci USA 88(8):3324–3328
Putnak R, Barvir DA, Burrous JM, Dubois DR, D’Andrea VM, Hoke CH, Sadoff JC, Eckels KH (1996) Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174(6):1176–1184
Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, Hayes CG, Stout R, Murphy GS (2003) Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315(2):345–352
Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garcon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35):4442–4452
Rothman AL (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11(8):532–543
Rouwendal GJ, Mendes O, Wolbert EJ, Douwe de Boer A (1997) Enhanced expression in tobacco of the gene encoding green fluorescent protein by modification of its codon usage. Plant Mol Biol 33(6):989–999
Schillberg S, Fischer R, Emans N (2003) Molecular farming of recombinant antibodies in plants. Cell Mol Life Sci 60(3):433–445
Shin YJ, Hong SY, Kwon TH, Jang YS, Yang MS (2003) High level of expression of recombinant human granulocyte-macrophage colony stimulating factor in transgenic rice cell suspension culture. Biotechnol Bioeng 82(7):778–783
Shin YJ, Lee NJ, Kim J, An XH, Yang MS, Kwon TH (2010) “High-level production of bioactive heterodimeric protein human interleukin-12 in rice. Enzym Microb Technol 46(5):347–351
Sijmons PC, Dekker BM, Schrammeijer B, Verwoerd TC, van den Elzen PJ, Hoekema A (1990) Production of correctly processed human serum albumin in transgenic plants. Biotechnology 8(3):217–221
Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP (2008) Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78(3):426–433
Simmons M, Nelson WM, Wu SJ, Hayes CG (1998) Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58(5):655–662
Simmons M, Murphy GS, Hayes CG (2001) Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65(2):159–161
Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N, Paradkar V, Schlittler M, Carroll JA, Spatola L, Ward D, Ye G, Russell DA (2000) High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 18(3):333–338
Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R (2009) Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 5(1):33–40
Takaiwa F (2013) Increasing the production yield of recombinant protein in transgenic seeds by expanding the deposition space within the intracellular compartment. Bioengineered 4(3):136–139
Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, Deubel V, Mazie JC, Lafaye P (2001) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82(Pt 8):1885–1892
Trent D, Shin J, Hombach J, Knezevic I, Minor P (2010) WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11–12 May 2009. Vaccine 28(52):8246–8255
Uribe-Campero L, Monroy-Garcia A, Duran-Meza AL, Villagrana-Escareno MV, Ruiz-Garcia J, Hernandez J, Nunez-Palenius HG, Gomez-Lim MA (2015) Plant-based porcine reproductive and respiratory syndrome virus VLPs induce an immune response in mice. Res Vet Sci 102:59–66
Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP (2011) Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 85(2):341–351
Weiner HL, da Cunha AP, Quintana F, Wu H (2011) Oral tolerance. Immunol Rev 241(1):241–259
Whitehead SS, Blaney JE, Durbin AP, Murphy BR (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5(7):518–528
Acknowledgements
This study was supported by NRF-2014K1B1A1073861 through the National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT & Future Planning, and by the Ministry of Agriculture, Food and Rural Affairs (714001-07), Republic of Korea.
Author information
Authors and Affiliations
Contributions
M-YK conceived and designed the overall study. S-CH and N-XH performed the majority of experiments. S-CH and M-YK wrote the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Han, SC., Huy, NX. & Kim, MY. Enhanced expression of dengue virus EDIII-based tetravalent antigen protein using transgenic rice callus. Plant Biotechnol Rep 12, 207–215 (2018). https://doi.org/10.1007/s11816-018-0487-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11816-018-0487-6